General Forum, page-1610

Totally appreciate your view on being a better (metrics given,usability etc) product should mean more sales.

Unfortunately there are countless examples of better tech not being taken up vs the incumbent tech. There are many factors as to why but one of the major ones is cost deferential, switching cost and ultimately take up by industry participants.

If clinicians and doctors don't take it on board in a big way it likely won't disrupt the BP industry. Having better tech and also including a means for doctors to increase their billable's. That's a solid strategy. Being able to do so at around the same price point and also same
functionality...also a big positive in our favour.

It will come down to relationships building with the industry participants to begin with and then grow from their. The beauty of where things are at with globalisation and auplly chains is the reality is the CardieX Pulse could turn into the BP monitor of choice within the next 24 months, which of course would be huge... Excecution and aligning self interest appropriately will ultimately determine the success. I'm definitely leaning towards success but still a ways to go in proving up the market for CDX products.


The risk return metrics are ridiculous at these prices IMO so I have been and will continue to add small parcels when I can.